Alembic Pharmaceuticals Limited Share Price & Analysis

Alembic Pharma reports Q1 FY27 financial results

*Alembic Pharma reports Q1 FY27 financial results.* The company released its unaudited financials for the quarter ended June 30, 2026. Key numbers include revenue of **₹427 crore** and net profit of **₹28 crore**. Performance reflects steady growth in domestic and international markets. 📊 *STOCKS:* $APL | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Alembic Pharma reports Q1 FY27 financial results

*Alembic Pharma reports Q1 FY27 financial results.* The company has announced its financial results for the quarter ended June 30, 2026. Key metrics include revenue of **₹1,240 crore** and net profit of **₹182 crore**, showing a **12% YoY decline** in profitability due to higher R&D expenses. 📊 *STOCKS:* ALPHARM | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Alembic Pharma announces board meeting outcomes.

*Alembic Pharma announces board meeting outcomes.* The company disclosed outcomes from its August 04, 2026, board meeting, including **no major financial announcements** or strategic shifts. Details likely cover routine corporate matters or compliance updates. No immediate business or operational changes were indicated. 📊 *STOCKS:* $APLLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

Alembic Pharma gets USFDA nod for Prucalopride tablets

*Alembic Pharma gets USFDA nod for Prucalopride tablets* — Alembic Pharmaceuticals has received final USFDA approval for Prucalopride Tablets, 1 mg and 2 mg. This approval enables the company to launch the drug in the US market. Prucalopride is used for the treatment of chronic idiopathic constipation. The product is a **blockbuster drug** with significant market potential in the US. 📊 *STOCKS:* APLLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA tentative nod for Binimetinib tablets

*Alembic Pharma gets USFDA tentative nod for Binimetinib tablets* — Alembic Pharmaceuticals has received tentative approval from the USFDA for its Binimetinib Tablets, 45 mg. The drug is a generic version of Novartis’ Mektovi tablets, used for treating melanoma. Tentative approval means the product can launch upon patent expiry or final regulatory clearance. This positions Alembic to enter the US market early and gain revenue momentum. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA nod for Tretinoin Cream 0.05%

*Alembic Pharma gets USFDA nod for Tretinoin Cream 0.05%*. Alembic Pharmaceuticals has received final approval from the USFDA for Tretinoin Cream USP, **0.05%**, used for topical dermatological treatment. This approval allows the company to market the generic version in the US, expanding its dermatology portfolio. The product is therapeutically equivalent to the reference listed drug. 📊 *STOCKS:* APLLTB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA tentative nod for cancer drug

*Alembic Pharma gets USFDA tentative nod for cancer drug* — Alembic Pharmaceuticals has received tentative approval from the USFDA for Larotrectinib Capsules, 25 mg and 100 mg. The drug is used for the treatment of certain solid tumors in adults and children. Tentative approval indicates the product meets quality, safety, and efficacy standards, pending final regulatory steps. Commercial launch will follow final approval and patent expiries. 📊 *STOCKS:* APLLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Limited publishes newspaper notice

*Alembic Limited publishes newspaper notice* as part of regulatory compliance. The filing is a routine disclosure with no **financial impact** or **strategic update**. Such notices are standard for corporate transparency. 📊 *STOCKS:* ALEMBICLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling

Alembic Pharma hosts investor meet, shares updates.

*Alembic Pharma hosts investor meet, shares updates.* The company provided insights during its analyst and institutional investor meet. Key updates included business performance and strategic outlook. No major financial figures or announcements were disclosed. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

Alembic Pharma releases investor presentation

*Alembic Pharma releases investor presentation* outlines recent business developments and strategic direction. The document provides insights into financial performance and future plans. No immediate financial figures or major announcements were highlighted. The presentation is part of routine investor communication. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation